Kang YU: Clinical Trials

1 trial sponsored by Kang YU, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 unknown. 1 Not applicable.

By phase and status

PhaseTrialsStatus
Not applicable1Unknown 1

Follow Kang YU: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
CAR-CD19 T cell, CAR-BCMA T cell, CAR-GPC3 T cell - B Cell Lymphoma, B Cell Leukemia
Not applicableUnknownKang YU182017-12-292020-10-08

Conditions studied

Carcinoma, Hepatocellular (1)  ·  Leukemia, B-Cell (1)  ·  Lymphoma, B-Cell (1)  ·  Neoplasms, Plasma Cell (1)  ·  Pancreatic Neoplasms (1)

Interventions

Cyclophosphamide (1)  ·  fludarabine (1)

Countries

China (1)

Top investigators

Mengtao Zhou, MD (1)  ·  Songfu Jiang, MD (1)

Results publications

PMID 34935483